Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14308 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Graeme F Murray und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Huntington Health, Pasadena, California, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Clonal Evolution, Recurrence. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Clonal evolution (CE) is a driving force behind the development and progression of acute myeloid leukemia (AML). Advances in molecular and cytogenetic assays have improved the depth and breadth of detection of CE in AML, which is defined here as a detected change in cytogenetic or molecular profile at relapsed or refractory (RR) disease. In this study, we demonstrate the clinical impact of CE in a cohort of patients with RR AML treated between 2013 and 2023. We discovered CE is significantly more frequent in relapsed disease (58.2%, [46.6%, 69.2%]) than in refractory disease (21.1%, [14.4%, 29.2%], p < 0.001). CE negatively impacts prognosis when detected by conventional karyotyping in refractory disease (4.2 vs. 13.9 months, p < 0.011). In contrast with prior literature, CE had no impact on overall survival if detected in relapsed disease. Surprisingly, those who achieved negative measurable residual disease (MRD) were no more likely to eliminate their original clone than those who did not ( p = 1). We found several cytogenetic and molecular signatures which may predispose to CE: aberrations of chromosome 17, trisomy 8, TP53 , KRAS , and FLT3 ‐TKD. Finally, physicians were less likely to retreat those with CE with IC after receiving IC as first‐line therapy (35.0% vs. 70.9%, p = 0.004). This study illustrates the role of CE in chemotherapy‐resistant AML; we identify unique cytogenetic and molecular signatures that define a subset of patients associated with a dismal prognosis. As next‐generation sequencing panels expand and new methods to characterize cytogenetic abnormalities emerge, our findings establish a basis for future studies investigating the prognostic and therapeutic impact of CE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Huntington Health, Pasadena, California, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Hematology and Oncology, Department of Internal Medicine, Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, Virginia, USA.
- Department of Internal Medicine, Virginia Commonwealth University Health, Richmond, Virginia, USA.
- Department of Pharmacy, Virginia Commonwealth University Health, Richmond, Virginia, USA.
- Department of Biostatistics, Virginia Commonwealth University School of Population Health, Richmond, Virginia, USA.
ORCID-Profile: Graeme F Murray
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- National Institute of Health
- National Cancer Institute
Zitieren
APA
Murray, G. F., Bouligny, I. M., Ho, T., Gor, J., Zacholski, K., Wages, N. A., Grant, S., & Maher, K. R. (2025). Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14308
Vancouver
Murray GF, Bouligny IM, Ho T, Gor J, Zacholski K, Wages NA, et al. Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia. European Journal of Haematology. 2025. doi:10.1111/ejh.14308
BibTeX
@article{Murray2025,
author = {Murray, Graeme F and Bouligny, Ian M and Ho, Thuy and Gor, Juhi and Zacholski, Kyle and Wages, Nolan A and Grant, Steven and Maher, Keri R},
title = {Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14308}
}
EUVIMED